Target species
Dogs and cats.
Indications for use for each target species
Symptomatic treatment of vomiting and reduced gastrointestinal motility associated with gastritis, pyloric spasm, chronic nephritis and digestive intolerance to some drugs.
Contraindications
Do not use in cases of gastrointestinal perforation or obstruction.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Special warnings
None
Special precautions for use
Special precautions for safe use in the target species:
The dosage must be adapted in animals with renal or hepatic insufficiency (due to an increase in the risk of side effects).
Avoid administration to animals with epilepsy. The dosage should be carefully observed, especially in cats and small breed dogs.
Following prolonged vomiting, consideration should be given to fluid and electrolyte replacement therapy.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Wash hands after administration to the animal.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
In case of accidental exposure by spillage onto the skin or eyes, wash immediately with abundant water. If an adverse effect occurs, seek medical advice immediately and show the package leaflet or the label to the physician.
Special precautions for the protection of the environment
Not applicable
Adverse events
Dogs, Cats:
Very rare (<1 animal/ 10, 000 animals treated, including isolated reports): | Extrapyramidal effecta (agitation, ataxia, abnormal positions and/or movements, prostration, tremors, aggressions, vocalisation) Allergic reaction |
a The observed effects are transient and disappear when treatment is stopped.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy, lactation or lay
Laboratory studies in laboratory animals have not produced any evidence of teratogenic of foetotoxic effects. However, studies in laboratory animals are limited and the safety of the active substance has not been evaluated in the target species. The use of the product during pregnancy and lactation must be made according to the benefit/risk assessment carried out by the veterinarian.
Interactions with other medicinal products and other forms of interaction
In cases of gastritis, avoid the co-administration of anticholinergic drugs (atropine) as they may counteract the effects of metoclopramide on gastrointestinal motility.
In cases of simultaneous diarrhoea, there is no contraindication to the use of anticholinergic drugs.
Concurrent use of metoclopramide with neuroleptics derived from phenothiazine (acepromazine) and butyrophenones increases the risk of extrapyramidal effects (see Adverse reactions).
Metoclopramide can potentiate the action of central nervous system depressants. If used concurrently, it is advised to use the lowest dosage of metoclopramide to avoid excessive sedation.
Administered routes and dosage
Intramuscular or subcutaneous use:
0.5 mg metoclopramide hydrochloride per kg body weight, if necessary repeated every 6-8 hours.
Symptoms of overdose (and where applicable, emergency procedures and antidotes)
Most of the clinical signs reported after an overdose are well known extrapyramidal side effects (see Adverse reactions). In the absence of a specific antidote, it is recommended to offer a calm environment to the animal until the extrapyramidal side effects disappear. Metoclopramide being rapidly metabolised and eliminated, side effects generally disappear quickly.
Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance
Not applicable
Withdrawal period
Not applicable